EyeGate acquired 100% of the shares in Panoptes. Co-founders Dr. Franz Obermayr and Dr. Stefan Sperl, as well as the institutional and strategic investors, sold their stake by way of a share swap and now hold an interest in EyeGate. Under the terms of the agreement, Panoptes becomes a wholly owned subsidiary of EyeGate, and its co-founders become part of the EyeGate management team.
DLA Piper advised Panoptes as well as its co-founders Dr. Franz Obermayr and Dr. Stefan Sperl and other shareholders. The team was led by Vienna-based Corporate partner Christoph Mager, counsel Johanna Höltl and senior associate Christian Knauder.
Commenting, DLA Piper’s partner Christoph Mager, said: “We are very pleased to have advised Panoptes Pharma on this strategically important transaction, which is testament to the Panoptes team’s success in developing their novel and highly innovative products.”
Based in Vienna, Panoptes Pharma Gmbh is a privatively held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need.
EyeGate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treatingdiseases and disorders of the eye. The company is listed on the Nasdaq and is headquartered in Waltham, Massachusetts.